Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
28 Novembre 2023 - 10:30PM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies for patients with autoimmune diseases,
today announced that Steven Nichtberger, M.D., Chief Executive
Officer, will participate in a fireside chat at the 6th Annual
Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023
at 8:20 a.m. ET in Miami, FL.
A live webcast of the presentation will be available on the News
and Events section of the Company’s website at
www.cabalettabio.com. Replays will be available on the website for
30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™ platform
encompasses two strategies: the CARTA (chimeric antigen receptor T
cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing
fully human CD19-CAR T, as the lead product candidate being
evaluated in systemic lupus erythematosus, myositis, systemic
sclerosis and generalized myasthenia gravis, and the CAART
(chimeric autoantibody receptor T cells) strategy, with multiple
clinical-stage candidates, including DSG3-CAART for mucosal
pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The
expanding CABA™ platform is designed to develop potentially
curative therapies that offer deep and durable responses for
patients with a broad range of autoimmune diseases. Cabaletta Bio’s
headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
William GramigStern Investor Relations,
Inc.william.gramig@sternir.com
Grafico Azioni Cabaletta Bio (NASDAQ:CABA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Cabaletta Bio (NASDAQ:CABA)
Storico
Da Giu 2023 a Giu 2024